COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Yang, M. C. [1 ]
Tan, E. C. H. [1 ]
机构：
[1] Natl Taiwan Univ, Taipei 10764, Taiwan
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.110
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN19
引用
收藏
页码：A736 / A736
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of gefitinib for first-line treatment of advanced non-small cell lung cancer: A Markov model-based analysis
    Liu, P. H.
    Hu, F. C.
    Wang, J. D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A64 - A64
  • [32] COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE
    Chouaid, C.
    Bensimon, L.
    Tardu, J.
    Millier, A.
    Insinga, R.
    Rai, A.
    Levy-Bachelot, L.
    Levy, P.
    [J]. VALUE IN HEALTH, 2020, 23 : S433 - S433
  • [33] EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Fong, Thomas
    Morgensztern, Daniel
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (03) : 303 - 310
  • [34] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Mo, Xiuting
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Shimozuma, Kojiro
    [J]. CLINICAL DRUG INVESTIGATION, 2022, 42 (07) : 599 - 609
  • [35] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Xiuting Mo
    Kensuke Moriwaki
    Kosuke Morimoto
    Kojiro Shimozuma
    [J]. Clinical Drug Investigation, 2022, 42 : 599 - 609
  • [36] OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA
    Zhou, J.
    Jiang, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S54 - S54
  • [37] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ROMANIA
    Ciuleanu, T. E.
    Dediu, M.
    Minea, L. N.
    Baculea, S.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A38 - A38
  • [38] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [39] Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
    Khan, Iftekhar
    Morris, Stephen
    Hackshaw, Allan
    Lee, Siow-Ming
    [J]. BMJ OPEN, 2015, 5 (07):
  • [40] Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States
    Criss, Steven D.
    Mooradian, Meghan J.
    Watson, Tina R.
    Gainor, Justin F.
    Reynolds, Kerry L.
    Kong, Chung Yin
    [J]. JAMA NETWORK OPEN, 2019, 2 (09)
12345